Nutra Pharma, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.
According to the company, Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.
The company has claimed that the product is is all natural, non-addictive, non-narcotic, non-opiate and more potent than Morphine. Rik Deitsch, chairman and CEO of Nutra Pharma Corporation, said: “Successfully submitting the final packaging and labeling to the FDA was the final step required for Nutra Pharma to begin selling and marketing Cobroxin. As we move forward with this launch, we plan to have Cobroxin available for sale at select online and brick-and-mortar retailers as early as October.”
Paul Reid, CEO of ReceptoPharm, said: “Based on the positive feedback we have already received from pharmacists and consumers about Cobroxin, we are now even more confident that this drug will soon become the preferred OTC pain reliever for those with moderate to severe chronic pain. In addition to our focus on Cobroxin, we are continuing to finalize additional product formulations to bring to market, including a prescription-only analgesic and a pain reliever for the veterinary market.”